Methotrexate Versus Apremilast for Pruritus in Psoriasis
- Sponsor
- Zarmeen Khawar
- Study ID
- NCT07432386
- Phase
- PHASE4
- Status
- Not Yet Recruiting
Notify me when recruiting opens
Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.
Add your contact details and location so we can keep your interest tied to this study.
Conditions
- Pruritus
- Psoriasis
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 65 Years
- Healthy Volunteers
- Not accepted
Interventions
- Apremilast — DRUGOral Apremilast titrated to 30 mg twice daily for 8 weeks.
- Methotrexate — DRUGOral Methotrexate 10 mg once weekly for 8 weeks.
Study Details
This randomized controlled trial aims to compare the efficacy of Methotrexate versus Apremilast in reducing pruritus and improving quality of life in patients with psoriasis. Eighty patients aged 20 to 60 years with psoriasis involving more than 8% body surface area and associated pruritus will be enrolled and randomly assigned into two groups. Group A will receive oral Apremilast titrated to 30 mg twice daily, while Group B will receive oral Methotrexate 10 mg once weekly for 8 weeks. The primary outcome will be change in Dermatology Life Quality Index (DLQI) score at 8 weeks. Secondary outcomes include change in numerical rating scale for pruritus and assessment of adverse effects. The study will be conducted at Pakistan Emirates Military Hospital Rawalpindi.
Key Dates
- First listed
- Feb 25, 2026
- Start date
- May 14, 2026
- Status verified
- Feb 2026
- Primary completion
- Oct 14, 2026
- Completion
- Oct 14, 2026
Study Design
- Enrollment
- 80 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: Apremilast GroupParticipants will receive oral Apremilast titrated to 30 mg twice daily for 8 weeks.
- Experimental: Methotrexate GroupParticipants will receive oral Methotrexate 10 mg once weekly for 8 weeks.
Primary Outcome Measure
Change in Dermatology Life Quality Index (DLQI) Score [ Time Frame: 8 weeks ]
Central Contacts
- Zarmeen Khawar, MBBS+923331940829
Related Studies
- Stelara and Tremfya Pregnancy Exposure Registry OTIS Autoimmune Diseases in Pregnancy ProjectRecruiting · University of California, San Diego · La Jolla, California
- Regulation of Inflammatory Genes in PsoriasisRecruiting · University of Alabama at Birmingham · Birmingham, Alabama
- LTS of Siliq vs. Other Therapies Treating of Adults With Moderate-to-Severe PsoriasisEnrolling By Invitation · Bausch Health Americas, Inc. · Bridgewater, New Jersey
- An Open-Label, Pilot Study to Evaluate the Efficacy of Narrowband Ultraviolet-B Phototherapy Three Times Weekly for Twelve Weeks in Moderate-to-Severe Psoriasis PatientsRecruiting · Psoriasis Treatment Center of Central New Jersey · East Windsor, New Jersey